Metastatic Triple-Negative Breast Cancer

Abstract

Abstract Purpose of Review Triple-negative breast cancer (TNBC) is a heterogeneous disease group with a known aggressive phenotype and poor prognosis. To date, it remains a challenging disease given its lack of oncogenic targets as seen in hormone receptor + or HER2 + breast cancers, and limited efficacy with traditional chemotherapy. This article is a review of the latest key literature in the management of metastatic TNBC and offers a glimpse of ongoing drug development. Recent Findings Recent paradigm-shifting trials led to the incorporation of immune checkpoint inhibitors with chemotherapy in the frontline setting for TNBC with positive PDL1-expression. Novel antibody–drug conjugates with new targets (Trop2, HER2) now offer additional treatment options for metastatic TNBC. Summary There have been significant strides in understanding the tumor-immune microenvironment and molecular vulnerabilities in TNBC. As the treatment of metastatic TNBC evolves rapidly, novel combination therapies and therapeutic strategies will continue to improve patient outcomes.